VivoSeq
Other

Conditioning

0

Pipeline Programs↗

16

Active Trials↗

3

Companies Involved↗

Conditioning is an early-stage landscape with 0 programs across 3 companies. The most active players are Eisai, Sangamo Therapeutics, Jasper Therapeutics, Inc..

Intelligence

Pipeline Metrics

Competitive Density

33/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

77/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eisai logo

Eisai

0 programs

PreclinicalS

Sangamo Therapeutics

0 programs

PreclinicalJ

Jasper Therapeutics, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

75

clinical trials

Completed27 · 36%
Unknown status24 · 32%
Recruiting9 · 12%
Terminated7 · 9%
Not yet recruiting5 · 7%
Active, not recruiting2 · 3%
Other1 · 1%

Clinical Trials

Trial Activity

75 trials

BeFluBu vs FluBuRux Conditioning in Haploidentical HCT
Recruiting·SSt. Petersburg State Pavlov Medical University·Phase 2·NCT06477549·220 enrolled
Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)
Recruiting·FFirst Affiliated Hospital of Zhejiang University·N/A·NCT07183878·138 enrolled
Two Step Haplo With Radiation Conditioning
Recruiting·TThomas Jefferson University·Phase 2·NCT05031897·63 enrolled
PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity
Recruiting·FFederal Research Institute of Pediatric Hematology, Oncology and Immunology·Phase 2·NCT06199427·100 enrolled
A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL
Recruiting·TThe First Affiliated Hospital of Zhengzhou University·Phase 2·NCT06557161·170 enrolled
A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL
Recruiting·TThe First Affiliated Hospital of Zhengzhou University·Phase 2·NCT06564545·276 enrolled
Conditioning Regimen of Melphalan-busulfan and Fludarabine: a Randomized Study of Different Dose of Melphalan
Recruiting·SShanghai Jiao Tong University School of Medicine·Phase 3·NCT06829472·120 enrolled
VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS
Recruiting·NNavy General Hospital, Beijing·Phase 1/2·NCT06471946·54 enrolled
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Recruiting·—·Phase 1/2·NCT03311503·12 enrolled
Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL
Active, not recruiting·SStanford University·Phase 1·NCT05507827·22 enrolled
Taxi STEP (Social Networks, Technology, and Exercise Through Pedometers)
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Preclinical·NCT03010163·290 enrolled
Mitoxantrone Hydrochloride Liposome Combined With BU/Cy Were Used as a Conditioning Regimen for Patients With Intermediate/Adverse Risk or Persistently Positive MRD AML
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·N/A·NCT06758726·20 enrolled
Sequential and Personalized PK-guided Busulfan Administration in the Frame of the Conditiong Regimen for Allo-HSCT in Patients With Malignant Hemopathies Ineligible for the Standard Myeloablative Conditioning
Not yet recruiting·IInstitut Paoli-Calmettes·Phase 2·NCT04451200·82 enrolled
Modified Conditioning Regimen for CML-BP
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT07259161·40 enrolled
Combination of ATG-based Conditioning Regimen and PTCy for GVHD Prevention in Allo-HSCT After PD-1 Blockade
Not yet recruiting·—·Phase 2·NCT06238245·22 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)